ArticleCureus2026
Diffuse Facial Melasma and Lentigines Treated With the NewMelan Multimodal Depigmentation Protocol: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes a 75-year-old woman presenting with diffuse facial melasma, lentigines, and associated dyschromia. The NewMelan multimodal depigmentation protocol, developed by Dr. Eduardo Krulig, was utilized in the management of this patient, who was treated under his supervision. Clinical examination demonstrated bilateral facial hyperpigmentation with uneven skin tone and photoaging-related pigmentary changes consistent with mixed melasma and lentiginous pigmentation. A physician-supervised depigmentation regimen was initiated. During the first week, the depigmenting product was applied three times daily, followed by twice daily applications during the second week. After 15 days, the protocol continued with once daily application as part of the maintenance regimen. Marked clinical improvement in facial hyperpigmentation and skin tone uniformity was observed within approximately two weeks of treatment initiation. Serial clinical photography demonstrated substantial reduction in pigmentation intensity, near-complete resolution of the most prominent melasma lesions, and improvement in overall facial appearance. Post-treatment, the patient was instructed to continue daily maintenance therapy. This case demonstrates short-term clinical improvement following treatment with the NewMelan multimodal depigmentation protocol. Further studies with larger patient populations and longer follow-up periods are necessary to evaluate long-term outcomes, recurrence rates, and broader clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.